<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719105</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC 575</org_study_id>
    <nct_id>NCT03719105</nct_id>
  </id_info>
  <brief_title>Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma</brief_title>
  <official_title>Induction Chemo-Immunotherapy Followed by Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-cell or NK Lymphoma/Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients are in 2 cohorts:

      Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified
      SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young
      adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX)
      (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide,
      doxorubicin, and prednisone in children, adolescent, and young adults with advanced
      peripheral T-cell lymphoma (non-anaplastic large cell lymphoma or non-NK lymphoma/leukemia) .

      Both groups proceed to allogeneic stem cell transplant with disease response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohort 1 and 2 will be based on initial diagnosis.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>1 year</time_frame>
    <description>to assess overall response rate following chemoimmunotherapy induction therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>event free survival</measure>
    <time_frame>2 year</time_frame>
    <description>to determine the event free survival after induction chemoimmunotherapy and allogeneic stem cell transplantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>NK-Cell Lymphoma</condition>
  <condition>NK-Cell Leukemia</condition>
  <condition>Peripheral T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with aggressive NK cell leukemia or stage III or IV extranodal NK/T-cell lymphoma, nasal type.
Chemotherapy Regimen:
mSMILE: Methotrexate Day 1, Ifosfamide Days 2-4, Dexamethasone Days 2-4, Etoposide Days 2-4, calaspargase pegol Day 8. For patients in CR and no available allogeneic SCT can receive up to 2 additional cycles of mSMILE.
Pembrolizumab: For patients in PR/MR/NR/PD after 2 cycles of mSMILE.
Allogeneic Stem Cell Transplant if donor available and not in PD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with stage III or IV peripheral T-cell lymphoma-NOS, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, or enteropathy-associated T-cell lymphoma (other histologies will be considered after case-by-case discussion with Study Chairs and Executive Vice-Chairs).
Chemotherapy Regimen:
Cycle 1 &amp; 2: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 3 &amp; 5: Brentuximab vedotin Day 1, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 4 &amp; 6: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Allogeneic Stem Cell Transplant if donor available and not in PD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pralatraxate,</intervention_name>
    <description>Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Patients will receive Ifsofamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Patients will receive dexamethasone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Patients will receive etoposide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calaspargase pegol</intervention_name>
    <description>Patients will receive pegaspargase as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Patients will receive prednisone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <description>Patients will receive brentuximab vedotin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must weigh at least 10 kilograms at the time of the study enrollment.

          -  Diagnosis

        Newly diagnosed patients with histologically proven mature T- and NK- cell neoplasms:

        COHORT 1

          -  Aggressive NK cell leukemia (ICD-O code 9948/3)

          -  Extranodal NK/T-cell lymphoma, nasal type (ICD-O code 9719/3) COHORT 2

          -  Enteropathy-associated T-cell lymphoma (ICD-O code 9717/3)

          -  Hepatosplenic T-cell lymphoma (ICD-O code 9716/3)

          -  Peripheral T-cell lymphoma, non-otherwise specified (ICD-O code 9702/3)

          -  Angioimmunoblastic T-cell lymphoma (ICD-O code 9705/3)

          -  Other mature T- and NK-cell neoplasm histologies will considered after case-by-case
             discussion with Study Chairs and executive Vice-Chair Patients with lymphoma must have
             stage III or IV disease (See Appendix III for Staging).

               -  Organ Function Requirements

        Adequate liver function defined as:

          -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age.

          -  ALT (SGPT) &lt; 3 x ULN for age.

        Adequate cardiac function defined as:

          -  Shortening fraction of ≥ 27% by echocardiogram, or

          -  Ejection fraction of ≥ 50% by radionuclide angiogram.

        Adequate pulmonary function defined as:

        • Patients with a history of pulmonary dysfunction must have no evidence of dyspnea at
        rest, no exercise intolerance due to pulmonary insufficiency, and a pulse oximetry &gt; 92%
        while breathing room air unless current dysfunction is due to the lymphoma, in which case
        the patient is eligible.

        Exclusion Criteria:

          -  Alk+ or Alk- Anaplastic Large Cell Lymphoma (ALCL)

          -  Patients with active CNS disease.

          -  Patients with stage I or stage II disease (See Appendix III for Staging).

          -  Patients who have received any prior cytotoxic chemotherapy for the current diagnosis
             of NHL.

          -  Previous steroid treatment and/or radiation treatment are not allowed unless they are
             used for emergency management. Patients who have received emergency irradiation and/or
             steroid therapy will be eligible only if started on protocol therapy not more than one
             week from the start of radiotherapy or steroids.

          -  Female patients who are pregnant. Pregnancy tests must be obtained in girls who are
             post menarchal.

          -  Lactating females, unless they have agreed not to breastfeed their infants.

          -  Patients with Down syndrome.

          -  Patients taking CYP3A4 substrates with narrow therapeutic indices. Patients (COHORT 2
             ONLY) chronically receiving medications known to be metabolized by CYP3A4 and with
             narrow therapeutic indices (See Appendix V). The topical use of these medications (if
             applicable) is allowed.

          -  Patients taking CYP3A4 inhibitors. Patients (COHORT 2 ONLY) chronically receiving
             drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment
             (See Appendix V). The topical use of these medications (if applicable) is allowed.

          -  Patients taking CYP3A4 inducers. Patients (COHORT 2 ONLY) chronically receiving drugs
             that are known potent CYP3A4 inducers within 12 days prior to study enrollment (See
             Appendix V).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>31 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Cairo, MD</last_name>
    <role>Study Director</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Xavier</last_name>
    <phone>(205) 638-6763</phone>
    <email>axavier@peds.uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Harrison</last_name>
    <phone>6172857844</phone>
    <email>lauren_harrison@nymc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Cairo, MD</last_name>
      <phone>914-594-3650</phone>
      <email>mitchell_cairo@nymc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Harrison, MSN</last_name>
      <phone>617-285-7844</phone>
      <email>lauren_harrison@nymc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Mitchell Cairo</investigator_full_name>
    <investigator_title>Executive Vice-Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

